Edgewise Therapeutics Appoints Abby H. Bronson, M.B.A., as Vice President, Patient Advocacy and External InnovationJuly 8, 2020 -
There are no upcoming events.
Edgewise is proud to list our investors
Our team of over 80 distinguished scientific, medical, investment and other professionals manages over $13 billion across public and private company investments worldwide.
Our mission is to be a supportive owner of the Novo Group companies and to make a growing and positive impact on health, science and society by generating attractive long-term returns on the assets of the Novo Nordisk Foundation.
USVP healthcare team has a unique competence in investing in medical devices, biotechnology and healthcare information technology sectors, with a focus on therapeutic medical devices that enable new or less invasive procedures, molecularly targeted protein or small molecule therapeutics, and information technology-enabled healthcare services, which improve the quality of care and/or significantly reduce costs.
We work with experienced management teams that have developed novel product programs and platforms exemplified by several key characteristics – including large unmet medical needs, strong science, well differentiated technologies, and high-quality pre-clinical and clinical development programs.
Deerfield is an investment management firm committed to advancing healthcare through investment, information and philanthropy.
As of 2018, CureDuchenne’s portfolio includes 16 wide-ranging projects with 4 successful exits. Investments from CureDuchenne Ventures have successfully leveraged more than $1.3 billion in follow-on financing from venture capital, biotech, and pharmaceutical companies to fund emerging projects to find treatments for Duchenne.